16 research outputs found
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
Background: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to
treat human immunodeficiency virus type 1 (HIV-1)
infection are not clear. We compared treatment with
the protease inhibitor indinavir in addition to zidovudine
and lamivudine with treatment with the two nucleosides
alone in HIV-infected adults previously treated
with zidovudine.
Methods: A total of 1156 patients not previously
treated with lamivudine or protease inhibitors were
stratified according to CD4 cell count (50 or fewer vs.
51 to 200 cells per cubic millimeter) and randomly
assigned to one of two daily regimens: 600 mg of zidovudine
and 300 mg of lamivudine, or that regimen
with 2400 mg of indinavir. Stavudine could be substituted
for zidovudine. The primary end point was
the time to the development of the acquired immunodeficiency
syndrome (AIDS) or death.
Results: The proportion of patients whose disease
progressed to AIDS or death was lower with indinavir,
zidovudine (or stavudine), and lamivudine (6 percent)
than with zidovudine (or stavudine) and lamivudine
alone (11 percent; estimated hazard ratio,
0.50; 95 percent confidence interval, 0.33 to 0.76;
P�0.001). Mortality in the two groups was 1.4 percent
and 3.1 percent, respectively (estimated hazard
ratio, 0.43; 95 percent confidence interval, 0.19 to
0.99; P=0.04). The effects of treatment were similar
in both CD4 cell strata. The responses of CD4 cells
and plasma HIV-1 RNA paralleled the clinical results.
Conclusions: Treatment with indinavir, zidovudine,
and lamivudine as compared with zidovudine and
lamivudine alone significantly slows the progression
of HIV-1 disease in patients with 200 CD4 cells or
fewer per cubic millimeter and prior exposure to zidovudine.
(N Engl J Med 1997;337:725-33.
Older Adults with Alzheimer’s Disease, Comorbid Arthritis and Prescription of Psychotropic Medications
OBJECTIVES: It is assumed that analgesia is underutilized among those with Alzheimer disease and that these patients may be inappropriately prescribed neuroleptics and benzodiazepines. The current study examines this assertion.DESIGN: For this study, prescription levels of analgesics and psychotropic medications for Alzheimer disease patients with (n=245) and without (n=215) musculoskeletal conditions (ie, arthritis or rheumatism) are compared.SETTING: A national sample of community dwelling and institutionalized older adults was identified from the Canadian Study of Health and Aging* (CSHA).PARTICIPANTS: Persons from 36 cities and surrounding rural areas over 64 years of age were randomly identified for the CSHA from government health records in all but one province.MEASUREMENTS: Prescribed analgesic and psychotropic medications were examined, as well as dementia severity and dementia related behavioural disturbance.RESULTS: Less than half of Alzheimer patients with arthritis or rheumatism were treated for pain (ie, 109 of 245 patients); they were also more likely to be prescribed benzodiazepines compared with Alzheimer patients without musculoskeletal conditions (subsequent to initial consideration for analgesia, dementia severity and dementia-related behaviours; äX2[ädf =1] =3.97, P=0.046).CONCLUSIONS: These findings are in accord with prior research attesting to the undertreatment of pain among older adults. These results can be generalized with greater confidence, given the random composition of the patient sample.Peer Reviewe
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Progress in the field of antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1) infection has brought the end of the zidovudine-monotherapy era,
1
–
3
an improved understanding of the pathogenesis of HIV-1 disease,
4
–
9
demonstrations of the prognostic importance of plasma HIV-1 RNA quantification,
10
–
17
and the availability of increasingly potent therapeutic agents. Much of this progress is linked to the introduction of the HIV-protease inhibitors, drugs that inhibit the processing of Gag and Gag–Pol polyprotein precursors and thus prevent the maturation of virions.
18
–
20
Trials of HIV-protease inhibitors have shown beneficial effects on CD4 cell counts and plasma HIV-1 . .Â
Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium
A phase I clinical trial was conducted in which recombinant adenovirus containing the cystic fibrosis trans-membrane regulator (CFTR) (Ad2/CFTR) was administered by bronchoscopic instillation or aerosolization to the lungs of cystic fibrosis (CF) patients. In this paper, we evaluate the efficiency of Ad2/CFTR-mediated transduction of bronchial airway cells. The ability of an Ad2/CFTR vector to transduce airway cells was first evaluated in patients to whom the vector was administered by bronchoscopic instillation. Cells at the administration site were collected 2 days after treatment by bronchoscopic brushing. Ad2-specific CFTR DNA was detected in four of five individuals by PCR, and Ad2-specific CFTR RNA was detected in three of five individuals by RT-PCR. Ad2/CFTR-mediated transduction of airway epithelial cells was then determined in CF individuals receiving this vector by aerosol inhalation. Ad2-specific CFTR DNA was detected in 13 of 13 individuals 2 days after aerosolization, and in 3 of 5 individuals 7 days after aerosolization. Ad2-specific RNA was detected in 4 of 13 individuals on day 2, but was not detected in the 5 individuals tested on day 7. The percentage of airway epithelial cells containing nuclear-localized vector DNA was \u3c or =2.4% as determined by fluorescence in situ hybridization (FISH). However, in some cases, a high percentage of nonepithelial mononuclear cells or squamous metaplastic epithelial cells was infected with the adenoviral vector. In conclusion, aerosol administration is a feasible means to distribute adenoviral vectors throughout the conducting airways, but improvements in adenovirus-mediated transduction of airway epithelial cells are necessary before gene therapy for CF will be effective
Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications
Cystic fibrosis (CF), an autosomal recessive disorder resulting from mutations in the cystic fibrosis trans-membrane conductance regulator (CFTR) gene, is the most common lethal genetic illness in the Caucasian population. Gene transfer to airway epithelium, using adenoviruses containing normal CFTR cDNA, leads to transient production of CFTR mRNA and, in some studies, to correction of the airway epithelial ion transport defect caused by dysfunctional CFTR. Inflammatory responses to the adenoviral vector have been reported, particularly at high viral titers. We evaluated the effects of adenovirus-mediated CFTR gene transfer to airway epithelium in 36 subjects with CF (34 individuals, 2 of whom received two separate doses of vector), 20 by lobar instillation and 16 by aerosol administration. Doses ranged from 8 x 10(6) to 2.5 x 10(10) infective units (IU), in 0.5-log increments. After lobar administration of low doses there were occasional reports of cough, low-grade temperature, and myalgias. At the highest lobar dose (2.5 x 10(9) IU) two of three patients had transient myalgias, fever, and increased sputum production with obvious infiltrates on CT scan. After aerosol administration there were no significant systemic symptoms until the 2.5 x 10(10) IU dose, when both patients experienced myalgias and fever that resolved within 24 hr. There were no infiltrates seen on chest CT scans in any of the patients in the aerosol administration group. There were no consistent changes in pulmonary function tests or any significant rise in serum IgG or neutralizing antibodies in patients from either group. Serum, sputum, and nasal cytokines, measured before and after vector administration, showed no correlation with adenoviral dose. Gene transfer to lung cells was inefficient and expression was transient. Cells infected with the vector included mononuclear inflammatory cells as well as cuboidal and columnar epithelial cells. In summary, we found no consistent immune response, no evidence of viral shedding, and no consistent change in pulmonary function in response to adenovirus-mediated CFTR gene transfer. At higher doses there was a mild, nonspecific inflammatory response, as evidenced by fevers and myalgias. Overall, vector administration was tolerated but transfer of CFTR cDNA was inefficient and transgene expression was transient for the doses and method of administration used here